Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and Nutraceutical products in various dosage forms, including tablets, capsules, oral liquids, powders, oils, and external preparations like balms, creams, and gels.
The company operates as a Contract Development and Manufacturing Organization (CDMO), serving both domestic and international markets such as Sri Lanka, Singapore, and the USA. Its products combine classical Ayurvedic principles with modern nutraceutical science to address areas like liver care, women’s health, bone and joint health, cognitive support, and respiratory wellness.
Business verticals:
It has a manufacturing facility in Gujarat covers about 10,763 sq. ft., equipped with modern infrastructure, including 13 air handling units, separate processing areas, and quality control systems. The facility is GMP, WHO-GMP, FSSC 22000, ISO 9001:2015, ISO 45001:2018, and Halal certified, with an FSSAI license.
| Investory Category | Subscription Percentage | Amount Raised (₹ Crores) |
|---|---|---|
| Qualified Institutional Buyers (QIBs) | 50% | 688000 crores |
| Non-Institutional Investors (NIIs | 15% | 206400 crores |
| Retail Individual Investors (RIIs) | 35% | 481600 crores |
Accretion Nutraveda Ltd’s total income 0 by 0.00% and total expenses 0 by 0.00%, resulting in an EBITDA 0 by 0.00% and a profit after tax (PAT) 0 by 0.00% between March 31, 2025 and March 31, 2026.
Experienced promoters and management Team
Diverse product portfolio
Commitment to quality standards
Relationships with clients and suppliers
Established business process and management framework
| Allotment Date | Listing Date |
|---|---|
| 02 Feb '26 | 04 Feb '26 |
| Minimum Lot Size | -- |
| Maximum Lot Size (Retail) | -- |
The lot size of Accretion Nutraveda Ltd ipo has been designed to ensure broad participation while maintaining optimal price discovery.